Disclosure of interest: Edoardo Ricci: nothing to disclose, Giovanni Furlanis: nothing to disclose, Milos Ajevi: nothing to disclose, Emanuele Vincis: nothing to disclose, Gabriele Prandin: nothing to disclose, Laura Mancinelli: nothing to disclose, Federica Palacino: nothing to disclose, Magda Quagliotto: nothing to disclose, Paola Caruso: nothing to disclose, Marcello Naccarato: nothing to disclose, Paolo Manganotti: nothing to disclose E-Posters - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.02 - ACUTE MANAGEMENT - Thrombolysis or thrombectomy P2081 - ESOC25-1546 ADVANCE CONSENT FOR PARTICIPATION IN ACUTE STROKE TRIALS (ACTION): 6-MONTH RESULTS OF A FEASIBILITY STUDY Michel Shamy 1,2 , Ubong Udoh 1 , Emma Cummings 1 , Rena Patricia Seeger 2 , Brian Dewar 1 , Dar Dowlatshahi 1,2 1 Ottawa Hospital Research Institute, Ottawa, Canada, 2 Department of Medicine, University of Ottawa, Ottawa, Canada Background and Aims: Obtaining consent for participation in acute stroke trials is widely recognized as a significant challenge
The use of Melanotan peptide offers a convenient alternative to traditional sun exposure by promoting tanning even with minimal sunlight exposure, as demonstrated using animal models
Treatment is provided through a licensed healthcare provider after consultation and screening
Maintain protein intake at 1.6 g to 2.2 g per kg of body weight and include micronutrients (vitamin C, zinc, magnesium) that contribute to collagen synthesis and tissue repair
Well assess your situation, determine whether BPC-157 is appropriate, and build a protocol at no cost to you
